Accelerating adolescent HIV research in low-income and middle-income countries: evidence from a research consortium.
Journal
AIDS (London, England)
ISSN: 1473-5571
Titre abrégé: AIDS
Pays: England
ID NLM: 8710219
Informations de publication
Date de publication:
01 12 2021
01 12 2021
Historique:
entrez:
6
12
2021
pubmed:
7
12
2021
medline:
3
2
2022
Statut:
ppublish
Résumé
Many adolescents and young adults (AYA) have unmet HIV prevention needs. We describe the Prevention and Treatment through a Comprehensive Care Continuum for HIV-affected Adolescents in Resource Constrained Settings (PATC3H) consortium organization, transition milestones, and youth engagement strategies. The PATC3H consortium focuses on reducing HIV incidence and related health disparities among AYA. Organizational data were obtained from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and supplemented with a brief survey completed by study principal investigators. Transition from the initial phase (years 1 and 2) to the subsequent phase (years 3 and 5) was contingent on meeting prespecified milestones. We reviewed the structure and function of the research consortium, identified shared elements of transition milestones, and examined common youth engagement strategies. The PATC3H consortium supports eight research studies through a milestone transition mechanism. The consortium includes AYA HIV research studies in seven countries - Brazil, Kenya, Mozambique, Nigeria, South Africa, Uganda, and Zambia. The NIH request for applications required transition milestones that included early consultation with stakeholders. The transition milestones required by NIH for the eight studies included early consultation with health and policy stakeholders, pilot intervention data, and commitment from national government stakeholders. All studies provided multiple pathways for AYA engagement, including AYA advisory boards and youth-led research studies. Data suggest that requiring milestones to transition to the final phase may have facilitated health and policy stakeholder engagement and enhanced formative assessment of regulatory protocols. These data have implications for designing engaged research studies in low and middle-income countries.
Identifiants
pubmed: 34870930
doi: 10.1097/QAD.0000000000003049
pii: 00002030-202112010-00011
pmc: PMC8901045
mid: NIHMS1732174
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
2503-2511Subventions
Organisme : NICHD NIH HHS
ID : UH3 HD096875
Pays : United States
Organisme : NICHD NIH HHS
ID : UG3 HD096914
Pays : United States
Organisme : NICHD NIH HHS
ID : UH3 HD096915
Pays : United States
Organisme : NICHD NIH HHS
ID : UG3 HD096908
Pays : United States
Organisme : NICHD NIH HHS
ID : UH3 HD096914
Pays : United States
Organisme : NICHD NIH HHS
ID : UH3 HD096920
Pays : United States
Organisme : NICHD NIH HHS
ID : UG3 HD096926
Pays : United States
Organisme : NICHD NIH HHS
ID : UH3 HD096908
Pays : United States
Organisme : NICHD NIH HHS
ID : UG3 HD096929
Pays : United States
Organisme : NICHD NIH HHS
ID : UG3 HD096906
Pays : United States
Organisme : NICHD NIH HHS
ID : UH3 HD096926
Pays : United States
Organisme : NICHD NIH HHS
ID : UG3 HD096875
Pays : United States
Organisme : NICHD NIH HHS
ID : UG3 HD096920
Pays : United States
Organisme : NIAID NIH HHS
ID : K24 AI143471
Pays : United States
Organisme : NICHD NIH HHS
ID : UG3 HD096915
Pays : United States
Organisme : NICHD NIH HHS
ID : UH3 HD096906
Pays : United States
Organisme : NICHD NIH HHS
ID : UH3 HD096929
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Références
J Int AIDS Soc. 2016 Nov 17;19(1):21263
pubmed: 27863535
J Int AIDS Soc. 2015 Dec 02;18(Suppl 6):20257
pubmed: 26639113
Lancet. 2016 Jun 11;387(10036):2423-78
pubmed: 27174304
J Int Assoc Provid AIDS Care. 2015 Nov-Dec;14 Suppl 1:S3-S34
pubmed: 26527218
Am J Community Psychol. 2020 Dec;66(3-4):256-266
pubmed: 32783253
J Acquir Immune Defic Syndr. 2010 Jul;54 Suppl 1:S1-4
pubmed: 20571417
Lancet HIV. 2020 Dec;7(12):e844-e852
pubmed: 33275917
BMC Infect Dis. 2021 May 31;21(1):505
pubmed: 34059014
J Int AIDS Soc. 2018 Oct;21 Suppl 7:e25174
pubmed: 30334358
J Int AIDS Soc. 2015 Feb 26;18(2 Suppl 1):20027
pubmed: 25724512
Trials. 2019 May 30;20(1):307
pubmed: 31146778
J Gen Intern Med. 2012 Aug;27(8):985-91
pubmed: 22528615
J Acquir Immune Defic Syndr. 2014 Jul 1;66 Suppl 2:S228-35
pubmed: 24918600
Lancet. 2012 Apr 28;379(9826):1630-40
pubmed: 22538178
PeerJ. 2019 Apr 12;7:e6762
pubmed: 30997295
J Int AIDS Soc. 2021 Feb;24(2):e25666
pubmed: 33569913
Prim Care. 2019 Dec;46(4):587-594
pubmed: 31655754
JMIR Res Protoc. 2020 Dec 16;9(12):e24043
pubmed: 33325838
Curr HIV/AIDS Rep. 2019 Feb;16(1):120-128
pubmed: 30707399
Lancet. 2009 Sep 12;374(9693):881-92
pubmed: 19748397
PLoS One. 2018 Feb 8;13(2):e0191251
pubmed: 29420549
J Acquir Immune Defic Syndr. 2018 Aug 15;78 Suppl 1:S16-S21
pubmed: 29994915
AIDS. 2017 Jul 1;31 Suppl 3:S191-S194
pubmed: 28665876
J Acquir Immune Defic Syndr. 2013 Jul;63 Suppl 2:S155-60
pubmed: 23764629
Curr Opin HIV AIDS. 2018 May;13(3):265-273
pubmed: 29528850
J Acquir Immune Defic Syndr. 2014 Jan 1;65 Suppl 1:S24-8
pubmed: 24321980
Health Syst Reform. 2017 Apr 3;3(2):69-73
pubmed: 31514676